Media Library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please e-mail your request to and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key Facts updated Jan 2018

Chief Executive Officer:
New York City
Web Address:
NYSE Listing:
Net Sales:
$20.8 billion in 2017
R&D Investment:
$4.8 billion* which included the discovery and development of new medicines for patients
Principal Locations:
*This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items. 
2017 Largest-Selling Brands:

OPDIVO®, $4.9 billion

ELIQUIS®, $4.9 billion

ORENCIA®, $2.5 billion

SPRYCEL®, $2.0 billion

YERVOY®, $1.2 billion

BARACLUDE®, $1.1 billion

SUSTIVA® franchise, $729 million

REYATAZ® franchise, $698 million

Hepatitis C franchise, $406 million

Selected Key Products:

Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™,ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol-Myers Squibb Corporate B-roll



This B-roll includes a collection of footage of Bristol-Myers Squibb's campus, corporate signage, research and development, and manufacturing facilities.


Usage Rights & Restrictions


This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.

Scientific Media Resources

Disease State Infographics

Disease State Infographics